Porvenir · Conversion Rate Optimisation for Pharmaceutical & Biotech Companies
Conversion Rate Optimisation
for
Pharmaceutical & Biotech Companies.
Conversion rate optimisation is the fastest way to grow revenue without increasing marketing spend. We audit your site, identify the exact friction points killing conversions, and run structured experiments that compound over time — turning the same traffic into significantly more leads and revenue.
Specialised for pharmaceutical & biotech companies. Pharmaceutical and biotech companies must build scientific credibility and investor confidence simultaneously.
What pharmaceutical & biotech companies search for
CRO agency for pharmaceutical & biotech companies — that is exactly what we deliver.
How we deliver conversion rate optimisation for pharmaceutical & biotech companies
A process built for
pharmaceutical & biotech companies.
CRO audit — heatmaps, session recordings, funnel analysis, and form analytics
Hypothesis development — prioritising tests by potential impact and implementation effort
A/B test design and execution — running statistically significant experiments
Results analysis and iteration — documenting learnings and compounding wins
What pharmaceutical & biotech companies gain
Real business outcomes
for pharmaceutical & biotech companies.
15–60% uplift in conversion rate on key commercial pages within 90 days
Lower customer acquisition cost from the same paid media budget
A CRO playbook with documented learnings that compounds in value over time
Why pharmaceutical & biotech companies invest in conversion rate optimisation
The problems we solve
for pharmaceutical & biotech companies.
Where we work
Serving pharmaceutical & biotech companies globally.
Other Web Design services for pharmaceutical & biotech companies
Conversion Rate Optimisation for Pharmaceutical & Biotech Companies
Ready to generate more
leads for your pharmaceutical & biotech?
Book a discovery call. No pitch, no pressure — just a focused conversation about where you are and where you want to be.